Filter posts

JOBS Act Deconstructed: Regulation D

More than 40 biotech companies have gone public using provisions made available to emerging growth …

JOBS Act Provides Innovators with Capital Boost

Despite all the talk of gridlock and polarization in Washington these days, successful, bipartisan pieces …

State Legislation Needed For Substitution of Interchangeable Biologics

A great deal of the media coverage relating to California’s Senate Bill 598  neglects to …

TTIP: Global Regulatory Cooperation and Convergence

The Transatlantic Trade and Investment Partnership (TTIP) initiative holds tremendous promise for the long-term competitiveness …

CSBI: New Study Outlines Potential Impact of Three Promising Tax Proposals

Ernst & Young recently released a study to determine the potential impact of three tax …

Propel Small Business Innovation through Tax Reform

As CEO of an emerging clinical-stage biotech company, I lose over $10 million each year. …

How the Orphan Drug Tax Credit Leverages MDA’s Fight against Rare Genetic Diseases

In the early 1950s, a small group of concerned parents, people with muscular dystrophy and …

TPP and Innovation in the Bioeconomy: The Need for 12 Years of Data Protection

A few weeks ago, BIO submitted a letter and white paper (PDF) to the U.S. Trade Representative outlining recommendations …

NORD Urges Congress: Don’t Cut Orphan Drug Tax Credit

This week, the National Organization of Rare Disorders (NORD) and more than 70 patient organizations …

The Hill: Innovation-focused tax reform for U.S. global competitiveness

The Hill Blog published an op-ed by Geoff Davis on ‘Innovation-focused tax reform for U.S. …